SCHEMBL18056458

SCHEMBL18056458

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C(C(=O)NNC(=S)Nc2ccc3[nH]ncc3c2)C1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.45
▸ TRPV1 Q8NER1 7/20 0.44
▸ ROCK2 O75116 8/20 0.43
▸ PIK3CD O00329 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX12 P18054 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ ROCK1 Q13464 3/20 0.42
▸ CYP3A4 P08684 1/20 0.41
▸ EP300 Q09472 1/20 0.41
▸ P2RX7 Q99572 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038300 0.83 EGFR (0.42) ROCK2NPC1ALDH1A1MAPTHPGD
SCHEMBL14514349 0.77 ROCK2 (0.63) ROCK2NPC1ALDH1A1MAPTRAB9A
SCHEMBL5817971 0.75 ROCK2 (0.64) ROCK2ROCK1CYP3A4
SCHEMBL312320 0.74 ROCK2 (0.68) ROCK2NPC1ALDH1A1MAPTRAB9A
SCHEMBL11889768 0.72 NPC1 (0.57) TRPV1ROCK2NPC1MAPTRAB9A
SCHEMBL625972 0.70 ROCK2 (0.66) POLBROCK2NPC1RAB9AROCK1
SCHEMBL16600091 0.70 POLB (0.52) POLBTRPV1ROCK2NPC1ALDH1A1
SCHEMBL6881915 0.70 PIK3CD (0.54) POLBROCK2PIK3CDMAPTCYP3A4
SCHEMBL6881911 0.70 PIK3CD (0.54) POLBROCK2PIK3CDMAPTCYP3A4
SCHEMBL23167233 0.70 ROCK2 (0.46) POLBTRPV1ROCK2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016138335-A1 INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE LYCERA CORPORATION (US) 2016-09-01 — — WO disclosed
Send feedback